Ken Griffin Mi Nk Therapeutics, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$0.84 - $1.12 $17,918 - $23,891
-21,332 Reduced 50.62%
20,809 $18,000
Q4 2023

Feb 14, 2024
BUY
$0.88 - $1.21 $37,084 - $50,990
42,141 New
42,141 $45,000
Q2 2023

Aug 14, 2023
BUY
$0.89 - $3.33 $45,432 - $169,989
51,048 New
51,048 $107,000

Others Institutions Holding INKT

# of Institutions
34
Shares Held
912K
Call Options Held
0
Put Options Held
0
View Full List

About MiNK Therapeutics, Inc.

INKT Quotes by TradingView
  • Ticker INKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,775,100
  • Market Cap $24.7M
  • Description
  • MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...
More about INKT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email